Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International Inks Deal With Eurobio Scientific for French Distribution of Kidney Test

NEW YORK – Proteomics International said Monday that it has signed a deal with Eurobio Scientific for the exclusive distribution of its PromarkerD diabetic kidney disease test in France.

Under the terms of the deal, which will last for five years and is extendable for additional five-year periods, Proteomics International will receive a payment for each PromarkerD test kit sold. Additional terms of the deal were not disclosed.

PromarkerD measures the levels of three plasma proteins — apoA4, CD5L, and IGFBP3 — and combines those measurements with an individual's age, HDL-cholesterol level, and eGFR to predict a type 2 diabetes patient's risk of developing diabetic kidney disease within four years.

According to Proteomics International, roughly 3.9 million people in France have type 2 diabetes, and the country has one of the highest rates of end-stage kidney disease in Europe.

Eurobio Scientific will become the exclusive distributors for the PromarkerD predictive test following a sub-distribution agreement with UK firm Apacor and under the terms of a master sub-distribution agreement between Apacor and Proteomics International. In 2023, Proteomics International extended by five years an ongoing UK distribution agreement for PromarkerD that it signed with Apacor in 2021.

"Eurobio Scientific's extensive distribution network across France ensures that our innovative PromarkerD predictive test can reach healthcare providers efficiently," said Richard Lipscombe, managing director of Proteomics International. "Eurobio Scientific's strong relationships with key stakeholders, robust market knowledge, and local expertise will drive demand for our test in this important market."